ZVRA — Zevra Therapeutics Inc.

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Zevra Therapeutics Inc.

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$10.95
Market Cap$620M
Float55.0M
Shares Outstanding59.1M
P/E (Forward)9.93
P/E (TTM)5.22
Price/Sales (TTM)5.07
vs. Analyst Target+110.0% to analyst PT
Profit Margin101.58%
Operating Margin (TTM)24.38%
Revenue (TTM)$122M
Dividend RateNone
Analyst Target Price$23.00 (7 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $13.3M -$12.8M $12.0M -$5.4M
2021 $28.6M -$8.6M $26.6M -$7.9M
2022 $10.2M -$26.8M $9.9M -$25.5M
2023 $27.5M -$46.0M $24.5M -$43.5M
2024 $23.6M -$106M $16.2M -$76.4M
2025 $106M $83.2M $90.0M $98.7M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $25.9M $74.7M
Sep 2025 $26.1M -$544,000
Dec 2025 $34.1M $12.2M
Mar 2026 $36.2M $37.9M

Ownership & Float

Insider Ownership1.4%
Institutional Ownership70.6%
Short Float9.1%
% of All Funds Holding1.63%
Number of Funds Holding134

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$10.20Near-term / short-term trend
Weekly40-Week SMA$9.33Medium-term trend
Weekly80-Week SMA$9.06Cyclical trend (business cycle)
Weekly200-Week SMA$6.98Secular trend (multi-year)
Monthly10-Month SMA$9.45Near-term monthly trend
Monthly20-Month SMA$8.97Medium-term monthly trend
Monthly40-Month SMA$7.26Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$11.00 resistance 2.26x 8 months ago
$6.90 support 1.49x 18 months ago
$6.50 support 3.23x 20 months ago
$4.90 support 2.65x 21 months ago

Historical Earnings Reactions (45 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.68% -0.62% 37.78% 23.24% -31.58%
1 Day -1.48% -1.32% 44.44% 25.88% -36.36%
1 Week 0.28% -1.05% 42.22% 40.00% -39.00%
2 Weeks -0.32% -2.73% 42.22% 60.47% -39.95%
1 Month 1.98% -1.42% 40.91% 76.41% -38.52%

Next earnings: July 25, 2026 (58 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan3.0%45.5%11
Feb4.5%54.5%11
Mar-4.3%27.3%11
Apr-2.3%36.4%11
May-3.7%63.6%11
Jun8.6%72.7%11
Jul1.8%45.5%11
Aug7.2%54.5%11
Sep-2.5%45.5%11
Oct-8.7%45.5%11
Nov4.7%45.5%11
Dec-3.0%45.5%11

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.16% 44.6% 522
Tuesday -0.16% 45.0% 576
Wednesday -0.04% 46.2% 572
Thursday 0.13% 48.0% 562
Friday 0.12% 47.2% 561

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 70.6%

Insider Transactions — Smart Summary

Total insider ownership: 1.4%

12-Month Insider Activity Summary

Total Filings14
Net Value-$1.7M
Net Shares Change258,184
% of Float0.5%
C-Suite Filings11
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
McFarlane Neil F. President and CEO -$853,425.3 1 N/A
Shih Alvin +$157,800 1 1 buy
Schafer Joshua CCO -$126,300.488 2 N/A
Thompson Rahsaan Chief Legal and Compliance -$56,281.872 2 N/A
Bode John B +$45,825 1 1 buy
Quartel Adrian W Chief Medical Officer -$40,035.909 1 N/A
FAVORITO TAMARA A +$24,718.01 1 1 buy
Sangiovanni Timothy J. SVP, Finance and Corp Controller -$15,442 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-02-02 – 2026-02-10 8 5 -$1.2M 8 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-09-16 FAVORITO TAMARA A +$24,718.01 Transaction at $7.79, now +40.7%
2025-09-15 Shih Alvin +$157,800 Transaction at $7.89, now +38.8%
2025-08-20 Bode John B +$45,825 Transaction at $9.16, now +19.5%
2026-02-04 Schafer Joshua CCO -$96,500.25 Transaction at $9.19, now +19.1%
2026-02-02 Thompson Rahsaan Chief Legal and Compliance -$36,009.672 Transaction at $8.83, now +24.1%
2026-02-02 Schafer Joshua CCO -$29,800.238 Transaction at $8.83, now +24.0%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Zevra Therapeutics Inc. (ZVRA) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ZVRA on Trend Edge →